TG Therapeutics Stock Jumps On Positive Results For Multiple Sclerosis TreatmentInvestors Business Daily • 12/10/20
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple SclerosisGlobeNewsWire • 12/10/20
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual MeetingGlobeNewsWire • 12/07/20
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual MeetingGlobeNewsWire • 12/07/20
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in BloodGlobeNewsWire • 12/02/20
TG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/30/20
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare ConferenceGlobeNewsWire • 11/13/20
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial ResultsGlobeNewsWire • 11/09/20
TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/04/20
TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic LeukemiaGlobeNewsWire • 10/21/20
TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular LymphomaGlobeNewsWire • 08/13/20
TG Therapeutics (TGTX) CEO, Michael Weiss on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial ResultsGlobeNewsWire • 08/10/20
Are You Looking for a Top Momentum Pick? Why TG Therapeutics (TGTX) is a Great ChoiceZacks Investment Research • 07/20/20
TG Therapeutics (TGTX) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 07/20/20
TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by UmbralisibGlobeNewsWire • 07/08/20
TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular LymphomaGlobeNewsWire • 06/17/20
TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation ConferenceGlobeNewsWire • 06/16/20